Truist Says Alkermes’ Alixorexton Data Lacks Detail Despite Phase 2 Success

Truist comments on Alkermes’ Phase 2 Vibrance-2 trial of alixorexton in narcolepsy type 2, noting "limited" details but strong patient engagement and maintaining a Buy rating with a $50 target.